Updated:
XOMA
XOMA, led by CEO Owen Hughes, manages a royalty portfolio of over 70 partnered biotech assets from Emeryville, CA.
XOMA
XOMA was founded in 1981 as a monoclonal antibody discovery company, but its modern identity began with a strategic pivot in 2017. After decades of antibody engineering that produced mid-stage pipeline failures, the company restructured into a royalty and milestone aggregator, acquiring streams on therapeutic candidates developed by other firms. Owen Hughes, appointed CEO in May 2022, previously served as XOMA's Chief Financial Officer, bringing continuity to a business model built on intellectual-property monetization rather than drug development. The firm manages a portfolio of over 70 preclinical, clinical, and commercial-stage assets, spanning endocrinology, oncology, cardiovascular disease, and ophthalmology. Its economics are driven by out-licensing agreements: XOMA earns royalties on commercial sales of partnered drugs and receives milestone payments when programs advance through regulatory gates. Known counter-parties include Novartis, which commercializes the anti-IL-1 antibody canakinumab (Ilaris) bearing a XOMA royalty, and Rezolute, a clinical-stage biotech developing therapies for rare metabolic diseases. In April 2023, XOMA acquired royalty and milestone interests from ATHA-101, a clinical-stage neurological candidate, adding to a pipeline of bets selectively sourced via secondary transactions. The Emeryville-headquartered firm operates with a lean team of roughly 15 professionals, reflecting its capital-light royalty model. A March 2024 transaction saw the company receive a $12 million milestone payment triggered by the FDA's acceptance of an IND application for a partnered program, underscoring the cash-generative mechanics of the royalty portfolio. Through subsidiary XOMA Technologies, the company retains legacy antibody discovery capabilities that it leverages selectively for third-party partnering. There is no disclosed philanthropic arm or formal co-investor club. XOMA occupies a niche distinct from venture creation and public-equity biotech investing: it acts as a financial backstop for smaller developers by purchasing partial royalty streams in exchange for upfront capital, while the operator continues to fund clinical development. This structure exposes XOMA to binary clinical and regulatory catalysts without the capital expenditure of a full-scale drug developer, a posture more akin to specialty-finance than healthcare venture capital.
General information
Firm type
Asset Manager
Year founded
1981
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Emeryville
Corporate office
Emeryville, California, United States
Principals
Owen Hughes
Chief Executive Officer
Thomas Burns
Chief Financial Officer
Sector focus
Frequently asked questions
What does XOMA actually own?
XOMA owns contractual rights to royalties and milestone payments on more than 70 preclinical, clinical, and commercial-stage therapeutic programs. These programs are developed and funded by partner companies; XOMA does not operate the trials or manufacture the drugs. Its largest known commercial royalty is on canakinumab (Ilaris), marketed by Novartis for several rare inflammatory conditions.
Who runs investment and portfolio decisions at XOMA?
Owen Hughes, as Chief Executive Officer, leads portfolio strategy, including the acquisition of new royalty streams and milestone interests. Hughes has been with XOMA since 2011 and served as CFO before becoming CEO in May 2022. Investment decisions are evaluated by a small executive team drawing on the firm's deep institutional knowledge of drug-approval pathways and deal structures.
How does XOMA source its royalty deals?
XOMA sources royalty acquisitions through a combination of direct outreach to biotech companies seeking non-dilutive capital, relationships with existing partners, and secondary purchases of royalty streams from original holders looking for liquidity. The firm typically targets clinical-stage programs where near-term regulatory or clinical catalysts offer visible milestone-payment triggers.
Is XOMA a biotech company or a royalty financier?
Since 2017, XOMA operates as a royalty and milestone aggregator, not a drug developer. While it retains a legacy antibody-discovery subsidiary, the business model revolves around purchasing partial royalty streams on third-party drug candidates. The company is listed on the Nasdaq biotechnology index, but its economic profile aligns closely with specialty-finance firms.
Does XOMA make equity investments or only royalty purchases?
XOMA primarily acquires royalty and milestone-payment streams rather than taking equity stakes in developers. Some transactions may include small equity components, but the core vehicle is a contractual right to a percentage of future drug revenue or a fixed milestone payment upon regulatory achievement.
What therapeutic areas does XOMA target?
The portfolio spans endocrinology, oncology, cardiovascular disease, ophthalmology, neurology, and rare disease. XOMA does not explicitly avoid any therapeutic area but favors programs with clear regulatory pathways and binary catalysts that can generate milestone payments or royalties within a defined timeframe.
How does XOMA generate revenue from its portfolio?
Revenue comes from two sources: royalties on net sales of approved drugs commercialized by partners, and milestone payments triggered by clinical or regulatory events such as FDA application acceptances, trial initiations, or drug approvals. A single milestone event can produce multimillion-dollar cash inflows, as seen in the $12 million milestone received in March 2024.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: